Nearly 80,000 workers in the Houston area travel at least 90 minutes each way for their jobs. Photo via Getty Images

If you’re a workday commuter in the Houston metro area, you may be among the many motorists who’ve cursed the snarled traffic on I-610/West Loop Freeway. This route routinely takes the crown as the most clogged roadway in Texas.

But imagine if you were one of the nearly 80,000 workers in the Houston area who travel at least 90 minutes each way for their jobs. That’s an even more gripe-worthy commuting scenario.

U.S. Census Bureau data gathered by Apartment List shows that as of 2022 in the Houston area, 79,645 workers were tagged as “super commuters.” These workers represent three percent of all commuters in the region.

The Houston area’s 2022 number is down slightly from the pre-pandemic year of 2019, when 82,878 workers across the region were super commuters, according to Apartment List.

Igor Popov, chief economist at Apartment List, says 3.7 million American workers spent at least 90 minutes traveling each way for their jobs in 2022. These extreme commutes are becoming more commonplace as suburban populations rise and employers pull back on remote work, he says.

Nationally, the number of super commuters jumped by 593,000 in 2022 compared with 2021, when the pandemic caused the figure to plummet by more than 1.5 million.

“Generally, super commuting is most common for transit users, workers who live on the fringes of the metropolitan area, or those who commute to separate metros entirely,” Popov says.

Super commuting is also common among high-income workers who are willing to travel longer distances for higher-wage jobs, according to Popov.

A recent study by Stanford University and travel data provider INRIX mostly aligns with the Census Bureau data cited by Apartment List.

Since the pandemic, the study says, the share of one-way commutes covering at least 40 miles has gone up in the country’s 10 largest metros, including Houston. In the Houston area, the share of one-way super commutes, which the study defines as those over 75 miles, grew 18 percent from 2019-20 to 2023-24.

Among the 10 areas examined in the study, a typical two-way super commute lasts nearly four hours and 40 minutes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.